abstract |
The invention discloses application of the Vande Thani (dasatinib) in the antitumor drug for preparing targeting EphB4, belong to pharmaceutical technology field.The present invention is by the above application of experimental verification Vande Thani, and molecular docking method, SPR methods and MST are the experimental results showed that Vande Thani can interact with EphB4.EphB4 kinase assays show that Vande Thani can obviously inhibit EphB4 kinase activities.Significantly inhibit K562 Leukaemia, the proliferation of JLTRG, H9.Meanwhile Vande Thani significantly inhibits signaling molecule p-PI3K p85/p55, PI3K the p85 expression in the downstreams EphB4, lowers the phosphorylation level of MEK and ERK.Therefore, experimental result of the invention fully supports application of the Vande Thani in the tumour medicine of anti-leukemia medicine and targeting EphB4. |